<DOC>
	<DOCNO>NCT00759928</DOCNO>
	<brief_summary>Two cohort patient enrol : Cohort A consist patient current smoker , Cohort B consist patient current nonsmoker . There 24 patient enrolled cohort . Nonsmokers patient consume tobacco nicotine-containing product 1 year start study . Patients classify current smoker must smoke minimum 10 cigarette per day 1 year . Patients smoke 1-9 cigarette per day 1 year , 10 cigarette per day le 1 year eligible study .</brief_summary>
	<brief_title>PK Trial Sorafenib &amp; Erlotinib Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>Compared supportive care alone , erlotinib associate improved overall survival patient Refractory Solid Tumors ; however , absolute benefit limited majority patient . Incorporating biologic agent second- third-line treatment setting may prove successful strategy improve treatment efficacy ( recently demonstrate several tumor type ) . Additionally , recent data suggest smoking may influence pharmacokinetic ( PK ) profile erlotinib increase metabolic clearance . Data suggest geometric mean erlotinib AUC ( 0-inf ) C ( 24h ) significantly decrease smoker compare nonsmoker ( Hamilton et al . 2006 ) . For reason , trial enroll separate cohort patient current smoker patient nonsmoker . Nonsmokers patient consume tobacco nicotine-containing product 1 year start study . Patients classify current smoker must smoke minimum 10 cigarette per day 1 year .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically confirm incurable solid tumor refractory standard treatment know standard treatment . 2 . Two cohort patient enrol : Cohort A consist patient current smoker , Cohort B consist patient current nonsmoker . Nonsmokers patient consume tobacco nicotinecontaining product 1 year start study . Patients classify current smoker must smoke minimum 10 cigarette per day &lt; 1 year . 3 . Patients must evaluable disease . 4 . Recovery toxic effect prior therapy grade 1 per National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 3.0 . 5 . Completion radiation therapy least 21 day prior start study treatment ( include palliative local radiation ) . 6 . An Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 7 . Absolute neutrophil count ( ANC ) &gt; 1,500/mL platelet &gt; 75,000/mL ( within 7 day prior study treatment ) . 8 . Hemoglobin &gt; 9 g/dL ( within 7 day prior treatment ) . Patients may transfuse receive erythropoietin maintain exceed level otherwise indicate . 9. International normalize ratio ( INR ) &lt; 1.5 prothrombin time ( PT ) /partial thromboplastin time ( PTT ) within normal limit ( WNL ) institution ( patient anticoagulation therapy ; patient receive anticoagulation treatment agent warfarin heparin may allow participate therapeutic range establish prior initiation study treatment ) . 10 . Serum creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) within 7 day prior study treatment . If absolute value great 2 mg/dL , creatinine clearance ( calculate accord CockcroftGault formula ) must &gt; 45 mL/min patient eligible study . 11 . Transaminases &lt; 3 x institutional ULN ( except know hepatic metastasis , wherein transaminase may &lt; 5 x institutional ULN ) . 12 . Total bilirubin &lt; 1.5 time ULN . 13 . Patients must able understand nature study , give write informed consent , comply study requirement . 14 . Agreement female patient childbearing potential male patient partner childbearing potential use effective form contraception prevent pregnancy treatment , minimum 90 day thereafter . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Exclusion 1 . Patients untreated brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Patients history brain metastasis treat surgery radiation therapy &gt; 4 week sign Central Nervous System ( CNS ) progression allow . 2 . Women pregnant lactating . 3 . Patients whose last dose chemotherapy , immunotherapy , investigational drug therapy complete &lt; 21 day prior receive study drug 4 . Significant cardiac disease within 90 day start study treatment include : superior vena cava syndrome ; new onset angina ; congestive heart failure ( CHF ) &gt; Class 2 per New York Heart Association ( NYHA ) classification ( see Appendix B ) ; ventricular arrhythmia ; valvular heart disease . 5 . Myocardial infarction ( MI ) within 6 month prior initiation study treatment . 6 . Cardiomegaly chest image CHF &gt; Class 2 per NYHA classification ( see Appendix B ) unless leave ventricular ejection fraction ( LVEF ) within normal range institution within 3 month initiate therapy . 7 . Poorly control hypertension ( define systolic blood pressure [ BP ] &gt; 150 mmHg and/or diastolic blood pressure &gt; 90 mmHg antihypertensive medication ) . 8 . Unstable angina ( anginal symptom rest ) . 9 . Cardiac ventricular arrhythmia require antiarrhythmic therapy . 10 . Presence cardiac disease , opinion investigator , increase risk ventricular arrhythmia . 11 . A serious active infection ( &gt; grade 2 ) time treatment 12 . A serious underlying medical condition would impair ability patient receive protocol treatment . 13 . A major surgical procedure within 28 day begin treatment , anticipation need major surgery course study . 14 . Any minor surgery must complete within 7 day prior begin study treatment . 15 . Use rifampin , St. John 's wort , potent inducer CYP3A4 permit Day 14 Day 15 study ( see Appendix C ) . 16 . Use ketoconazole potent inhibitor CYP3A4 permit Day 14 Day 15 study ( see Appendix C ) . 17 . Stroke transient ischemic attack ( TIA ) within past 6 month . 18 . Any prior history hypertensive crisis hypertensive encephalopathy . 19 . Pulmonary hemorrhage/bleeding event &gt; grade 2 within 28 day study treatment . 20 . Any nonpulmonary hemorrhage/bleeding event &gt; grade 3 within 28 day study treatment . 21 . Evidence history bleed diathesis coagulopathy . 22 . Serious nonhealing wound , ulcer , bone fracture . 23 . Known suspected allergy/hypersensitivity agent give course trial . 24 . Patients gastrointestinal ( GI ) tract disease , cause inability take oral medication , malabsorption syndrome , requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease . 25 . Patients smoke 19 cigarette per day year study entry patient smoke &lt; 1 year eligible study . 26 . Any condition impair patient 's ability swallow whole pill . 27 . Known human immunodeficiency virus ( HIV ) infection chronic active Hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Refractory Solid Tumors</keyword>
	<keyword>Unresectable Stage III/IV</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>